ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma

CAR-T Therapies Will Beat T-Cell Engagers To Market

 
• By Mandy Jackson
BCMA-targeting bispecifics are racing from Phase I into Phase II studies • Source: Shutterstock

More from Clinical Trials

More from R&D